two of the things I really liked about this at the time were :
1) test on Caucasian woman. So clearly planning for products in the USA and elsewhere.
2) the investigation verified clinical benefits to the skin rather than depth of penetration of product. 300% penetration improvement may sound good in marketing and may result in clinical benefits, BUT it is not itself a clinical benefit. The improvement in skin barrier function is an actual clinical benefit that customers should be able to notice.
- Forums
- ASX - By Stock
- P&G support OBJ tech 100%
two of the things I really liked about this at the time were :...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable